We measure every batch by the length of its fragments
PDRN is described by the length of its fragments, and the field measures that length in more than one way.
We describe our PDRN by fragment length, and the field gives that length in two units. Base pairs count the length of the DNA. Kilodaltons give the mass, and one base pair weighs about 660 daltons.
Products on the market span from about 80 to 2,200 base pairs, which is about 50 to 1,500 kilodaltons. We aim at 20 to 80 base pairs, or about 13 to 53 kilodaltons. A long fragment and a short one are different molecules, so we measure the distribution of every batch.
The field measures size by gel electrophoresis, by size-exclusion chromatography with light scattering, and lately by mass photometry.
Two papers from 2026, by Chen and colleagues and by Zhou and colleagues, show how much the answer depends on the method.
The answer also depends on how the measurement is set up.
We report our range by the distribution of every batch, and we keep the method that produced the number with the number.
About Synthena Pharmaceuticals
Synthena Pharmaceuticals is a pharmaceutical company founded in Hong Kong in July 2026 and focused on one substance, PDRN. Its aim is to turn PDRN into medicines made without animal-derived sources, produced within a defined fragment-length range and studied across five fields of human biology. Its most advanced programme is preclinical; no Synthena medicine has entered clinical trials or been approved for any indication.
This page describes research and development. It does not establish the safety or efficacy of any Synthena medicine.
